A designer sugar, KarboLyn®, leads to tighter sugar control than glucose in a pre-diabetic cohort

Submission date	Recruitment status No longer recruiting	Prospectively registered		
16/11/2016		☐ Protocol		
Registration date 22/11/2016	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 24/01/2019	Condition category Nutritional, Metabolic, Endocrine	[] Individual participant data		

Plain English summary of protocol

Background and study aims

Type 2 diabetes mellitus (T2DM) is a growing problem worldwide. People with T2DM have difficulty controlling their blood sugar (glucose) as they do not produce enough insulin to function properly (insulin deficiency), or that the body's cells don't react to insulin as they should do (insulin resistance). Prediabetes is a condition where a person's blood sugar levels are higher than normal, but nor high enough to be classified as T2DM. If left untreated, then prediabetes can turn into T2DM. In people with T2DM and diabetes, when sugar is consumed it causes blood sugar levels to rise as there is not enough insulin (or the insulin is ineffective) to store the sugar for when it's needed later. KarboLyn® is a designer sugar originally developed for athletes interested in carbohydrate loading (a technique used to maximize storage of energy for exercise). It has been shown to be quickly stored in the body without the ending 'crash' that often accompanies these energy bursts. The aim of this study is to look at the way KarboLyn® is broken down and stored in healthy volunteers and those with prediabetes and T2DM compared to glucose.

Who can participate?

In part one, healthy volunteers and those with prediabetes aged 21 or over can take part. In part two, diabetics aged 21 or over can take part.

What does the study involve?

In part one, participants are asked to fast for eight hours before the study visit and are randomly allocated to one of two groups. Those in the first group consume 50g KarboLyn® and those in the second group consume 50g glucose (sugar). All participants are then asked to walk on a treadmill for two hours. At the start of the study and then 15, 30, 45, 60, 75, 90, 105, and 120 minutes after consuming the sugar, participants stop and have a blood sample taken which is used to measure blood sugar levels.

In part two, participants are asked to fast for eight hours before the study visit and not to take their diabetes medication. At the study visit, all participants consume 10g KarboLyn® and are then asked to walk on a treadmill for two hours. At the start of the study and then 15, 30, 45, 60, 75, 90, 105, and 120 minutes after consuming the sugar, participants stop and have a blood

sample taken which is used to measure blood sugar levels. One week later, participants return for a second study visit which is exactly the same except they consume 10g glucose instead.

What are the possible benefits and risks of participating?

There are no direct benefits involved with participating. There is a small chance of pain or discomfort when blood samples are taken. In part two, diabetic patients may experience a spike in blood sugar which may make them feel unwell.

Where is the study run from?
Montana Medical Research Incorporated (USA)

When is the study starting and how long is it expected to run for? November 2013 to May 2016

Who is funding the study? All American Pharmaceutical (USA)

Who is the main contact?

1. Ms Wendy Jones (scientific)

WLJ_1998@yahoo.com

2. Dr Jeff Golini (public)

jeffg@allamericanpharmaceutical.com

Contact information

Type(s)

Scientific

Contact name

Ms Wendy Jones

Contact details

Royal Knight Incorporated 1204 Harbor Drive SE, Ste - 100 Rochester United States of America 55904 +1 507 289 8192 WLJ_1998@yahoo.com

Type(s)

Public

Contact name

Dr Jeff Golini

ORCID ID

http://orcid.org/0000-0002-4301-3800

Contact details

All American Pharmaceutical
2376 Main Street
Billings
United States of America
59105
+1 406 245 5793
jeffg@allamericanpharmaceutical.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 001

Study information

Scientific Title

KarboLyn®, leads to glucose control in a pre-diabetic cohort

Study objectives

The aim of this study is to observe the effect of KarboLyn® Vs glucose has on blood sugar response in normal, pre-diabetic, and Type 2 non-insulin dependent diabetic volunteers.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Part 1: Quorum Review IRB Board, 07/01/2014, ref: 29443/1

Part 2: Integ-review Board, 13/05/2015, ref: KL003

Study design

Part 1: Randomised controlled trial

Part 2: Non-randomised study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Other

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Diabetes

Interventions

Part 1:

After an 8-hour fast (minumum), normal and pre-diabetic volunteers are randomized to one of two groups.

Group 1: Participants receive 50g KarboLyn® Group 2: Participants receive 50g glucose

Following consumption of the study sugar, participants are asked to walk on a treadmill (~1mph) for a period of 2 hours. At baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, and 120 minutes, participants stop and have blood samples drawn in order to measure blood glucose levels.

Part 2:

All diabetic volunteers are withdrawn from their oral diabetic medication for one cycle and fast for a minimum of 8 hours prior to commencement of the study. All participants receive KarboLyn® (10 grams) and are then asked to walk on a treadmill (~1mph) for a period of 2 hours. At baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, and 120 minutes, participants stop and have blood samples drawn in order to measure blood glucose levels.

After one week 'off', the same volunteers are treated in the above manner prior to receiving 10 grams of glucose. Blood draw conditions and timing are the same.

Intervention Type

Not Specified

Primary outcome measure

Blood sugar is measured by blood draws and standard glucose testing at '0' (before consumption), and at 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, and 120 minutes for all volunteers.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/11/2013

Completion date

13/05/2016

Eligibility

Key inclusion criteria

Part 1:

Healthy volunteers:

- 1. Aged 21 years and over
- 2. Healthy (not a pre-diabetic or diabetic)
- 3. Normal blood sugar level (fasting glucose is less than or equal to 100 mg/dl)

Pre-diabetics:

- 1. Aged 21 years and over
- 2. Pre-diabetic not currently taking any diabetic related medication to control blood sugar level
- 3. Fasting blood sugar is greater than 100 mg/dl and less than 130 mg/dl

Part 2:

- 1. Aged 21 years and over
- 2. Diabetic (fasting blood sugar is between 125 mg/dl and 200 mg/dl)

Participant type(s)

Mixed

Age group

Adult

Sex

Both

Target number of participants

Normal controls: 24 / pre-diabetics: 12 / Type 2 diabetics: 6

Key exclusion criteria

Parts 1 and 2:

- 1. Pregnancy
- 2. Heath condition making participant unable to walk on a treadmill for 2 hours

Date of first enrolment

01/07/2014

Date of final enrolment

21/12/2015

Locations

Countries of recruitment

United States of America

Study participating centre Montana Medical Research Incorporated

2683 Palmer St, Ste B

Missoula United States of America 59808

Sponsor information

Organisation

All American Pharmaceutical

Sponsor details

2376 Main Street
Billings
United States of America
59105
+1 406 245 5793
jeffg@allamericanpharmaceutical.com

Sponsor type

Industry

ROR

https://ror.org/03x3d2a47

Funder(s)

Funder type

Industry

Funder Name

All American Pharmaceutical

Results and Publications

Publication and dissemination plan

Planned publication in the Journal of Diabetes and Metabolic Disorders.

Intention to publish date

31/12/2016

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Wendy Lou Jones, MSc (WLJ_1998@yahoo.com) and Dr. Jeff Golini, PhD (drjeff@allamericanpharmaceutical.com)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2017	24/01/2019	Yes	No